Clinical Trials Browser

OTHER × Breast Neoplasms × Capecitabine × Clear all

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Phase 2 Recruiting

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Phase 2 Recruiting

Breast Neoplasms, Meningeal Neoplasms

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

Phase 2 Recruiting

Breast Neoplasms

NCT05693766 2026-01-20

INSIGHT

Phase 2 Recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06105684 2026-01-07

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT06085742 2025-12-19

BRE-08

Phase 2 Recruiting

Breast Neoplasms

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Phase 2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07158164 2025-11-13

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Phase 4 Recruiting

BreastGastrointestinalHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms

NCT06525766 2025-10-03

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast Neoplasms, Meningeal Neoplasms

NCT01354522 2025-06-15

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT07019337 2025-06-13

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07021261 2025-06-13

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Phase 3 Not yet recruiting

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Phase 2 Recruiting

Breast Neoplasms

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT05288777 2025-04-18

Breast53

Phase 2/3 Recruiting

Breast Neoplasms

NCT04296162 2025-04-17

ORCHID

Phase 2 Active not recruiting

Breast Neoplasms

NCT03377387 2025-04-15

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04768426 2025-03-20

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06787339 2025-01-22

Calorite

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT03872388 2024-10-02

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Phase 2 Terminated

6 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT06483386 2024-07-03

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04383275 2024-03-22

IRIS

Phase 2 Recruiting

Breast Neoplasms

NCT06313463 2024-03-15

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Phase 3 Recruiting

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06268652 2024-02-20

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01387295 2023-12-11

Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

Phase 2 Completed

38 enrolled 11 charts

Breast Neoplasms

NCT02754011 2023-12-07

GEP14-LEECAP

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT06156761 2023-12-05

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Phase NA Unknown

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Phase 2 Terminated

3 enrolled 6 charts

Breast Neoplasms